IL155818A0 - Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridyl-sulfonamide and cyclic oligosaccharides - Google Patents

Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridyl-sulfonamide and cyclic oligosaccharides

Info

Publication number
IL155818A0
IL155818A0 IL15581801A IL15581801A IL155818A0 IL 155818 A0 IL155818 A0 IL 155818A0 IL 15581801 A IL15581801 A IL 15581801A IL 15581801 A IL15581801 A IL 15581801A IL 155818 A0 IL155818 A0 IL 155818A0
Authority
IL
Israel
Prior art keywords
methylethylaminocarbonyl
methylphenylamino
sulfonamide
pyridyl
compositions
Prior art date
Application number
IL15581801A
Other languages
English (en)
Original Assignee
Pliva Pharm & Chem Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Pharm & Chem Works filed Critical Pliva Pharm & Chem Works
Publication of IL155818A0 publication Critical patent/IL155818A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL15581801A 2000-11-10 2001-01-31 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridyl-sulfonamide and cyclic oligosaccharides IL155818A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR20000765A HRP20000765A2 (en) 2000-11-10 2000-11-10 Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
PCT/HR2001/000004 WO2002038186A1 (en) 2000-11-10 2001-01-31 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides

Publications (1)

Publication Number Publication Date
IL155818A0 true IL155818A0 (en) 2003-12-23

Family

ID=10947206

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15581801A IL155818A0 (en) 2000-11-10 2001-01-31 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridyl-sulfonamide and cyclic oligosaccharides

Country Status (26)

Country Link
US (1) US7037928B2 (hu)
EP (1) EP1347780B1 (hu)
JP (1) JP2004513155A (hu)
KR (1) KR20030060929A (hu)
CN (1) CN1477977A (hu)
AR (1) AR026815A1 (hu)
AU (1) AU2001228721A1 (hu)
BG (1) BG107896A (hu)
BR (1) BR0115281A (hu)
CA (1) CA2428179A1 (hu)
CZ (1) CZ20031490A3 (hu)
DE (1) DE60125828T2 (hu)
EA (1) EA005111B1 (hu)
EE (1) EE200300197A (hu)
GE (1) GEP20043403B (hu)
HR (1) HRP20000765A2 (hu)
HU (1) HUP0400776A2 (hu)
IL (1) IL155818A0 (hu)
IS (1) IS6810A (hu)
MX (1) MXPA03004111A (hu)
NO (1) NO20032091L (hu)
PL (1) PL361667A1 (hu)
SK (1) SK6722003A3 (hu)
WO (1) WO2002038186A1 (hu)
YU (1) YU35303A (hu)
ZA (1) ZA200303601B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
ES2293530T3 (es) * 2004-01-22 2008-03-16 Pfizer, Inc. Derivados de sulfonamidas para el tratamiento de enfermedades.
CN100372534C (zh) * 2006-04-20 2008-03-05 南京海辰药业有限公司 托拉塞米冻干制剂及制备方法
BRPI0809655B8 (pt) 2007-04-13 2021-05-25 Millennium Pharm Inc uso de um composto e um agente terapêutico,composição farmacêutica,e,kit
BR102012009317B1 (pt) * 2012-04-20 2022-05-31 Universidade Federal De Minas Gerais - Ufmg Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo
WO2020141226A1 (en) * 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
CN113271923A (zh) 2019-01-04 2021-08-17 Sq创新股份公司 呋塞米的药物组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576511A (en) * 1897-02-02 Georg steinike and friedrich schmidt
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
WO1997021312A2 (en) * 1995-12-01 1997-06-12 Philips Electronics N.V. A digital cordless telephony system, a radio base station, and a combination of a radio base station and a cordless handset
US6828334B2 (en) * 2002-05-23 2004-12-07 Usv Limited Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition

Also Published As

Publication number Publication date
EA005111B1 (ru) 2004-10-28
DE60125828T2 (de) 2007-08-16
CA2428179A1 (en) 2002-05-16
JP2004513155A (ja) 2004-04-30
CN1477977A (zh) 2004-02-25
EA200300556A1 (ru) 2003-08-28
BG107896A (bg) 2004-01-30
KR20030060929A (ko) 2003-07-16
CZ20031490A3 (cs) 2003-08-13
PL361667A1 (en) 2004-10-04
EP1347780A1 (en) 2003-10-01
HRP20000765A2 (en) 2002-06-30
ZA200303601B (en) 2004-07-19
HUP0400776A2 (hu) 2004-08-30
AR026815A1 (es) 2003-02-26
MXPA03004111A (es) 2004-05-05
EE200300197A (et) 2003-08-15
GEP20043403B (en) 2004-06-10
SK6722003A3 (en) 2003-10-07
US20040039204A1 (en) 2004-02-26
BR0115281A (pt) 2003-07-29
NO20032091D0 (no) 2003-05-09
US7037928B2 (en) 2006-05-02
WO2002038186A1 (en) 2002-05-16
AU2001228721A1 (en) 2002-05-21
EP1347780B1 (en) 2007-01-03
YU35303A (sh) 2006-03-03
IS6810A (is) 2003-05-08
DE60125828D1 (de) 2007-02-15
NO20032091L (no) 2003-07-02

Similar Documents

Publication Publication Date Title
HUP0302893A3 (en) Non-imidazole aryloxypiperidines and pharmaceutical compositions containing them and their use
AU8670901A (en) Fabric care compositions comprising cationic silicones and methods employing same
HUP0400048A2 (hu) Ciklikus N-(aril-karbonil)-aminok és ezeket tartalmazó gyógyszerkészítmények
HUP0303621A3 (en) Pharmaceutical compositions containing combinations comprising an antidiarrheal agent and epothilone or an epothilone
AU6118001A (en) Combination therapeutic compositions and methods of use
IL141767A0 (en) Use of heteroaryl substituted n- (indole-2-carbonyl-) amides for treatment of infection
HUP0301482A3 (en) Quinolinnyl and benzothiazolyl ppar-gamma modulators pharmaceutical compositions containing them and their use
GB2368537B (en) Dynamic damper and dynamic damper-installed racket
GB2363721B (en) Skin-friendly absorbent articles and compositions
HUP0301713A3 (en) Pharmaceutical compositions containing propenone derivatives and their use
HUP0402318A3 (en) Pharmaceutical composition comprising cyclosporin and use thereof
AU2001257457A1 (en) Vibration dampening compositions and methods thereof
HUP0401733A3 (en) Cyclic amine-derivatives and pharmaceutical compositions containing them
IL155818A0 (en) Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridyl-sulfonamide and cyclic oligosaccharides
SG100745A1 (en) Ceramic composition and ceramic capacitor
PL367676A1 (en) Novel heterocyclic derivatives and medicinal use thereof
WO2002046156A3 (en) 4,4-DISUBSTITUTED PIPERIDINES AND THEIR METHODS OF USE
AU3022201A (en) Novel use of (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)- chromane and its physiologically aceptable salts
PL367639A1 (en) Novel heterocyclic compound and medicinal use thereof
EP1461450A4 (en) T-BET COMPOSITIONS AND METHOD OF USE THEREOF
HUP0204560A3 (en) Heterocyclic amide derivatives and pharmaceutical compositions containing them and their use
HUP0303936A3 (en) Novel composition and use
ATE350065T1 (de) Zusammensetzungen aus n- (methylethylaminocarbonyl)-4-(3- methylphenylamino)-3-pyridylsulfonamid und zyklischen oligonukleotiden
GB0013503D0 (en) Pharmaceutical compositions and their uses
EP1414427A4 (en) KAVALACTONE COMPOSITIONS AND METHODS OF USE